Cargando…

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

BACKGROUND: KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawamoto, Y, Tsuchihara, K, Yoshino, T, Ogasawara, N, Kojima, M, Takahashi, M, Ochiai, A, Bando, H, Fuse, N, Tahara, M, Doi, T, Esumi, H, Komatsu, Y, Ohtsu, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394966/ https://www.ncbi.nlm.nih.gov/pubmed/22617127 http://dx.doi.org/10.1038/bjc.2012.218

Ejemplares similares

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome
por: Robinson, S M, et al.
Publicado: (2013)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma
por: Nohata, N, et al.
Publicado: (2011)

Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin–integrin signalling in head and neck squamous cell carcinoma
por: Kinoshita, T, et al.
Publicado: (2013)

Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma
por: Nohata, N, et al.
Publicado: (2013)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis
por: Osawa, T, et al.
Publicado: (2013)

Tumour-suppressive function of SIRT4 in human colorectal cancer
por: Miyo, M, et al.
Publicado: (2015)

Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells
por: Yamamoto, K, et al.
Publicado: (2012)

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
por: Harada, Kazuaki, et al.
Publicado: (2019)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
por: Yoshino, H, et al.
Publicado: (2011)

Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
por: Hasebe, T, et al.
Publicado: (2011)

High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment
por: Ma, G-F, et al.
Publicado: (2014)

Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer
por: Miyamoto, K, et al.
Publicado: (2016)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location
por: Bae, J M, et al.
Publicado: (2013)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature
por: Fukumoto, I, et al.
Publicado: (2014)

Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer
por: Ngan, C Y, et al.
Publicado: (2007)

Identification and analysis of tumour-associated antigens in hepatocellular carcinoma
por: Shi, Y-Y, et al.
Publicado: (2005)

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
por: Seo, A N, et al.
Publicado: (2013)

Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis
por: Lee, Y S, et al.
Publicado: (2012)

Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation
por: Hiraoka, N, et al.
Publicado: (2010)

Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis
por: Kouzu, Y, et al.
Publicado: (2006)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma
por: Takeshita, N, et al.
Publicado: (2013)

Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma
por: Liao, Y H, et al.
Publicado: (2011)

MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers
por: Zhang, P, et al.
Publicado: (2010)

Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients
por: Wong, S C C, et al.
Publicado: (2011)

HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium
por: Kurosu, T, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tcjvlp3bfoc87eb6ccbva7nvhn